RxDoctor Payments Data

Hector Payares

Psychiatric/Mental Health · Miami, FLNPI 1275080558

Payments from drug & device makers

$5,599in general payments, 2019–2025

Across 194 payments — averaging $28.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$701
  • Alkermes, Inc.$407
  • Axsome Therapeutics, Inc.$400
  • Johnson & Johnson$341
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$5,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,599 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$17,501
Medicare patients
42
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate103$168,032
VraylarCariprazine Hcl61$99,089
Abilify MaintenaAripiprazole14$40,989
TrintellixVortioxetine Hydrobromide34$16,565
Quetiapine Fumarate347$4,051
Mirtazapine206$3,718
Buspirone Hcl273$3,069
Trazodone Hcl252$2,944
Olanzapine83$2,744
Duloxetine Hcl117$1,841
Escitalopram Oxalate239$1,457
Doxepin Hcl80$1,383
Sertraline Hcl201$1,299
Aripiprazole77$1,268
Venlafaxine Hcl ErVenlafaxine Hcl13$1,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,189$168,032103 claims
AbbVieVraylar$1,172$99,08961 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$701$40,98914 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$86$16,56534 claims
Almatica Pharma LLCSertraline Hcl$18$1,299201 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →